Shamburg News · 8-K filed Nov 16, 2026, 8:04 AM EST
Apnimed Reports Third Quarter 2026 Results; Oxnimbi NDA Under FDA Review, PDUFA Feb. 28, 2027
APMD · Apnimed, Inc.
- Earnings
- Materiality: high
On November 16, 2026, Apnimed, Inc. reported financial results for the quarter ended September 30, 2026, with a net loss of $29.5 million, compared with a net loss of $10.9 million a year earlier. Research and development expenses were $11.8 million and general and administrative expenses were $22.6 million for the quarter. The company reported $351.8 million in cash and cash equivalents and said its NDA for AD109 (proposed name Oxnimbi) remains under FDA review with a February 28, 2027 PDUFA goal date.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-462171.
Written from the filing by Shamburg Markets. Figures are as reported by the company.